<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>endocrinology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>endocrinology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes
Authors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.
Score: 2.1, Published: 2023-07-16 DOI: 10.1101/2023.07.13.23292628
Type 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/endocrinology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="endocrinology" />
<meta property="og:description" content="Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes
Authors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.
Score: 2.1, Published: 2023-07-16 DOI: 10.1101/2023.07.13.23292628
Type 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/endocrinology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-07-30T10:36:57+00:00" />
<meta property="article:modified_time" content="2023-07-30T10:36:57+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="endocrinology"/>
<meta name="twitter:description" content="Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes
Authors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.
Score: 2.1, Published: 2023-07-16 DOI: 10.1101/2023.07.13.23292628
Type 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "endocrinology",
      "item": "https://trxiv.yorks0n.com/posts/endocrinology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "endocrinology",
  "name": "endocrinology",
  "description": "Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes\nAuthors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.\nScore: 2.1, Published: 2023-07-16 DOI: 10.1101/2023.07.13.23292628\nType 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells.",
  "keywords": [
    
  ],
  "articleBody": " Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes\nAuthors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.\nScore: 2.1, Published: 2023-07-16 DOI: 10.1101/2023.07.13.23292628\nType 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells. While it is known that gene-environment interactions play a key role in triggering the autoimmune process leading to T1D, the pathogenic mechanism leading to the appearance of islet autoantibodies - biomarkers of autoimmunity - is poorly understood. Here we show that disruption of the complement system precedes the detection of islet autoantibodies and persists through disease onset. Our results suggest that children who exhibit islet autoimmunity and progress to clinical T1D have lower complement protein levels relative to those who do not progress within a similar timeframe. Thus, the complement pathway, an understudied mechanistic and therapeutic target in T1D, merits increased attention for use as protein biomarkers of prediction and potentially prevention of T1D.\nLatent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.\nAuthors: Lledo Delgado, A.; Preston-Hurlburt, P.; Lim, N.; Sumida, T. S.; Long, S. A.; McNamara, J.; Serti, E.; Higdon, L.; Herold, K. C.\nScore: 1.5, Published: 2023-07-13 DOI: 10.1101/2023.07.11.23292344\nTeplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment. Higher number of Tregs and partially exhausted CD8+ T cells were found in EBV seropositive individuals at the baseline in the TN10 trial and AbATE trial. Single cell transcriptomics and functional assays identified downregulation of the T cell receptor and other signaling pathways before treatment. Impairments in function of adaptive immune cells were enhanced by teplizumab treatment in EBV seropositive individuals. Our data indicate that EBV can impair signaling pathways generally in immune cells, that broadly redirect cell differentiation.\n",
  "wordCount" : "383",
  "inLanguage": "en",
  "datePublished": "2023-07-30T10:36:57Z",
  "dateModified": "2023-07-30T10:36:57Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/endocrinology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      endocrinology
    </h1>
    <div class="post-meta"><span>updated on July 30, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.07.13.23292628">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.07.13.23292628" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.07.13.23292628">
        <p class="paperTitle">Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.07.13.23292628" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.07.13.23292628" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Webb-Robertson, B.-J. M.; Nakayasu, E. S.; Dong, F.; Waugh, K.; Flores, J.; Bramer, L.; Schepmoes, A.; Gao, Y.; Fillmore, T.; Onengut-Gumuscu, S.; Frazer-Abel, A.; Rich, S.; Holers, M.; Metz, T.; Rewers, M.</p>
        <p class="info">Score: 2.1, Published: 2023-07-16 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.07.13.23292628' target='https://doi.org/10.1101/2023.07.13.23292628'> 10.1101/2023.07.13.23292628</a></p>
        <p class="abstract">Type 1 diabetes (T1D) is a chronic condition caused by autoimmune destruction of the insulin-producing pancreatic {beta}-cells. While it is known that gene-environment interactions play a key role in triggering the autoimmune process leading to T1D, the pathogenic mechanism leading to the appearance of islet autoantibodies - biomarkers of autoimmunity - is poorly understood. Here we show that disruption of the complement system precedes the detection of islet autoantibodies and persists through disease onset. Our results suggest that children who exhibit islet autoimmunity and progress to clinical T1D have lower complement protein levels relative to those who do not progress within a similar timeframe. Thus, the complement pathway, an understudied mechanistic and therapeutic target in T1D, merits increased attention for use as protein biomarkers of prediction and potentially prevention of T1D.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.07.11.23292344">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.07.11.23292344" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.07.11.23292344">
        <p class="paperTitle">Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.07.11.23292344" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.07.11.23292344" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Lledo Delgado, A.; Preston-Hurlburt, P.; Lim, N.; Sumida, T. S.; Long, S. A.; McNamara, J.; Serti, E.; Higdon, L.; Herold, K. C.</p>
        <p class="info">Score: 1.5, Published: 2023-07-13 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.07.11.23292344' target='https://doi.org/10.1101/2023.07.11.23292344'> 10.1101/2023.07.11.23292344</a></p>
        <p class="abstract">Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment. Higher number of Tregs and partially exhausted CD8&#43; T cells were found in EBV seropositive individuals at the baseline in the TN10 trial and AbATE trial. Single cell transcriptomics and functional assays identified downregulation of the T cell receptor and other signaling pathways before treatment. Impairments in function of adaptive immune cells were enhanced by teplizumab treatment in EBV seropositive individuals. Our data indicate that EBV can impair signaling pathways generally in immune cells, that broadly redirect cell differentiation.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
